|
1
|
Endo-Munoz L, Evdokiou A and Saunders NA:
The role of osteoclasts and tumour-associated macrophages in
osteosarcoma metastasis. Biochim Biophys Acta. 1826:434–442.
2012.PubMed/NCBI
|
|
2
|
Harting MT and Blakely ML: Management of
osteosarcoma pulmonary metastases. Semin Pediatr Surg. 15:25–29.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jia S and Li B: Osteosarcoma of the jaws:
Case report on synchronous multicentric osteosarcomas. J Clin Diagn
Res. 8:ZD01–ZD03. 2014.PubMed/NCBI
|
|
4
|
He JP, Hao Y, Wang XL, Yang XJ, Shao JF,
Guo FJ and Feng JX: Review of the molecular pathogenesis of
osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Egas-Bejar D, Anderson PM, Agarwal R,
Corrales-Medina F, Devarajan E, Huh WW, Brown RE and Subbiah V:
Theranostic profiling for actionable aberrations in advanced high
risk osteosarcoma with aggressive biology reveals high molecular
diversity: The human fingerprint hypothesis. Oncoscience.
1:167–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poletajew S, Fus L and Wasiutyński A:
Current concepts on pathogenesis and biology of metastatic
osteosarcoma tumors. Ortop Traumatol Rehabil. 13:537–545. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu C, Ping Y and Li X, Zhao H, Wang L, Fan
H, Xiao Y and Li X: Prioritizing candidate disease miRNAs by
integrating phenotype associations of multiple diseases with
matched miRNA and mRNA expression profiles. Mol Biosyst.
10:2800–2809. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gaál Z and Oláh E: MicroRNA-s and their
role in malignant hematologic diseases. Orv Hetil. 153:2051–2059.
2012.(In Hungarian). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin S, Pan L, Guo S, Wu J, Jin L, Wang JC
and Wang S: Prognostic role of microRNA-181a/b in hematological
malignancies: A meta-analysis. PLoS One. 8:e595322013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kalinowski FC, Brown RA, Ganda C, Giles
KM, Epis MR, Horsham J and Leedman PJ: microRNA-7: A tumor
suppressor miRNA with therapeutic potential. Int J Biochem Cell
Biol. 54:312–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Y, Chu H, Zhou Y, Wang J, Dong C and
Yin R: miR-365 functions as a tumor suppressor by directly
targeting CYR61 in osteosarcoma. Biomed Pharmacother. 98:531–537.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu L, Wang S, Lin X, Lu Y and Gu P:
MicroRNA-124a inhibits cell proliferation and migration in liver
cancer by regulating interleukin-11. Mol Med Rep. 17:3972–3978.
2018.PubMed/NCBI
|
|
13
|
Luo Z, Wu G, Zhang D, Liu J and Ran R:
microRNA 625 targets Yes associated protein 1 to suppress cell
proliferation and invasion of osteosarcoma. Mol Med Rep.
17:2005–2011. 2018.PubMed/NCBI
|
|
14
|
Wang N, Li P, Liu W, Wang N, Lu Z, Feng J,
Zeng X, Yang J, Wang Y and Zhao W: miR-141-3p suppresses
proliferation and promotes apoptosis by targeting GLI2 in
osteosarcoma cells. Oncol Rep. 39:747–754. 2018.PubMed/NCBI
|
|
15
|
He Y and Yu B: MicroRNA-93 promotes cell
proliferation by directly targeting P21 in osteosarcoma cells. Exp
Ther Med. 13:2003–2011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun Z, Liu Q, Hong H, Zhang H and Zhang T:
miR-19 promotes osteosarcoma progression by targeting SOCS6.
Biochem Biophys Res Commun. 495:1363–1369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai Q, Zeng S, Dai X, Wu J and Ma W:
miR-504 promotes tumour growth and metastasis in human osteosarcoma
by targeting TP53INP1. Oncol Rep. 38:2993–3000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu Z, Huang X, Huang X, Zou Q and Guo Y:
The inhibitory role of Mir-29 in growth of breast cancer cells. J
Exp Clin Cancer Res. 32:982013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lv M, Zhong Z, Huang M, Tian Q, Jiang R
and Chen J: lncRNA H19 regulates epithelial-mesenchymal transition
and metastasis of bladder cancer by miR-29b-3p as competing
endogenous RNA. Biochim Biophys Acta. 1864:1887–1899. 2017.
View Article : Google Scholar
|
|
20
|
Kwon JJ, Willy JA, Quirin KA, Wek RC, Korc
M, Yin XM and Kota J: Novel role of miR-29a in pancreatic cancer
autophagy and its therapeutic potential. Oncotarget. 7:71635–71650.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shin J, Shim HG, Hwang T, Kim H, Kang SH,
Dho YS, Park SH, Kim SJ and Park CK: Restoration of miR-29b exerts
anti-cancer effects on glioblastoma. Cancer Cell Int. 17:1042017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma J, Li T, Yuan H, Han X, Shui S, Guo D
and Yan L: MicroRNA-29a inhibits proliferation and motility of
schwannoma cells by targeting CDK6. J Cell Biochem. 119:2617–2626.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ding Q, Chang CJ, Xie X, Xia W, Yang JY,
Wang SC, Wang Y, Xia J, Chen L, Cai C, et al: APOBEC3G promotes
liver metastasis in an orthotopic mouse model of colorectal cancer
and predicts human hepatic metastasis. J Clin Invest.
121:4526–4536. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fabbri M, Garzon R, Cimmino A, Liu Z,
Zanesi N, Callegari E, Liu S, Alder H, Costinean S,
Fernandez-Cymering C, et al: MicroRNA-29 family reverts aberrant
methylation in lung cancer by targeting DNA methyltransferases 3A
and 3B. Proc Natl Acad Sci USA. 104:15805–15810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boosani CS and Agrawal DK: PTEN
modulators: A patent review. Expert Opin Ther Pat. 23:569–580.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao ZQ, Wang JF, Chen DH, Ma XS, Wu Y,
Tang Z and Dang XW: Long non-coding RNA GAS5 suppresses pancreatic
cancer metastasis through modulating miR-32-5p/PTEN axis. Cell
Biosci. 7:662017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang P, Guan Q, Zhou D, Yu Z, Song Y and
Qiu W: miR-21 inhibitors modulate biological functions of gastric
cancer cells via PTEN/PI3K/mTOR pathway. DNA Cell Biol. 37:38–45.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo J, Xiao Z, Yu X and Cao R: miR-20b
promotes cellular proliferation and migration by directly
regulating phosphatase and tensin homolog in prostate cancer. Oncol
Lett. 14:6895–6900. 2017.PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hall PA, Levison DA, Woods AL, Yu CC,
Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover
R, et al: Proliferating cell nuclear antigen (PCNA)
immunolocalization in paraffin sections: An index of cell
proliferation with evidence of deregulated expression in some
neoplasms. J Pathol. 162:285–294. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moldovan GL, Pfander B and Jentsch S:
PCNA, the maestro of the replication fork. Cell. 129:665–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Zeng C, Tu M, Jiang W, Dai Z, Hu Y,
Deng Z and Xiao W: MicroRNA-200b acts as a tumor suppressor in
osteosarcoma via targeting ZEB1. Onco Targets Ther. 9:3101–3111.
2016.PubMed/NCBI
|
|
33
|
Yin Z, Ding H, He E, Chen J and Li M:
Up-regulation of microRNA-491-5p suppresses cell proliferation and
promotes apoptosis by targeting FOXP4 in human osteosarcoma. Cell
Prolif. 50:e123082017. View Article : Google Scholar
|
|
34
|
Wang X, Liu S, Cao L, Zhang T, Yue D, Wang
L, Ping Y, He Q, Zhang C, Wang M, et al: miR-29a-3p suppresses cell
proliferation and migration by downregulating IGF1R in
hepatocellular carcinoma. Oncotarget. 8:86592–86603.
2017.PubMed/NCBI
|
|
35
|
Shi C, Ren L, Sun C, Yu L, Bian X, Zhou X,
Wen Y, Hua D, Zhao S, Luo W, et al: miR-29a/b/c function as
invasion suppressors for gliomas by targeting CDC42 and predict the
prognosis of patients. Br J Cancer. 117:1036–1047. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao S, Cheng C, Chen H, Li M, Liu K and
Wang G: IGF1 3′UTR functions as a ceRNA in promoting angiogenesis
by sponging miR-29 family in osteosarcoma. J Mol Histol.
47:135–143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hong Q, Fang J, Pang Y and Zheng J:
Prognostic value of the microRNA-29 family in patients with primary
osteosarcomas. Med Oncol. 31:372014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang YK, Xi WY, Xi RX, Li JY, Li Q and Gao
YE: MicroRNA-494 promotes cervical cancer proliferation through the
regulation of PTEN. Oncol Rep. 33:2393–2401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hodakoski C, Fine B, Hopkins B and Parsons
R: Analysis of intracellular PTEN signaling and secretion. Methods.
77-78:164–171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li L, Zhu X, Shou T, Yang L, Cheng X, Wang
J, Deng L and Zheng Y: MicroRNA-28 promotes cell proliferation and
invasion in gastric cancer via the PTEN/PI3K/AKT signalling
pathway. Mol Med Rep. 17:4003–4010. 2018.PubMed/NCBI
|
|
42
|
Li J, Li C, Li H, Zhang T, Hao X, Chang J
and Xu Y: MicroRNA 30a 5p suppresses tumor cell proliferation of
human renal cancer via the MTDH/PTEN/AKT pathway. Int J Mol Med.
41:1021–1029. 2018.PubMed/NCBI
|
|
43
|
Zhao D, Chen Y, Chen S, Zheng C, Hu J and
Luo S: MiR-19a regulates the cell growth and apoptosis of
osteosarcoma stem cells by targeting PTEN. Tumour Biol.
39:10104283177053412017. View Article : Google Scholar : PubMed/NCBI
|
